In this episode of the Orange Pill Podcast, we unpack the federal class action lawsuit alleging deceptive labeling practices on dietary supplements sold through one of the world’s largest online retailers. Plaintiffs claim the company systematically omits mandatory disclaimers and promotes unapproved health claims—leaving consumers under the false impression that the products are FDA-approved.

With the court denying a motion to dismiss, discovery will now proceed into not only the purchased supplements, but potentially 1.6 million unpurchased products as well. What does this mean for regulatory enforcement, consumer protection, and industry compliance? We break down the case's broader implications for structure-function claim oversight, advertising integrity, and the future of supplement sales in digital marketplaces.